Patents Issued in January 7, 2020
  • Patent number: 10526271
    Abstract: Half salts of certain synthetic auxin herbicides are provided. These half salts are useful for controlling unwanted plant growth. The half salts have low solubility in water, low volatility relative to commercial compositions of the corresponding synthetic auxin herbicides, and offer comparable herbicidal performance when compared to existing salts of the synthetic auxin herbicides.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: January 7, 2020
    Assignee: Dow AgroSciences LLC
    Inventors: Lei Liu, Holger Tank, Melissa Gail Olds, Stephen L. Wilson
  • Patent number: 10526272
    Abstract: An object of the present invention is to provide a method for efficiently eliminating water from a composition containing an acrylic acid derivative and water. This problem is solved by a method for eliminating water from a composition A containing: (A) an acrylic acid derivative represented by Formula (I): wherein R1 and R2 are identical or different, and each represents alkyl, fluoroalkyl, aryl that may have one or more substituents, halogen, or hydrogen, R3 represents alkyl, fluoroalkyl, aryl that may have one or more substituents, or hydrogen, and X represents alkyl, fluoroalkyl, halogen, or hydrogen; and (B) water, the method comprising step A of bringing the composition A into contact with a zeolite.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: January 7, 2020
    Assignee: DAIKIN INDUSTRIES, LTD.
    Inventors: Makoto Matsuura, Yosuke Kishikawa, Asako Yoshiyama, Sumi Ishihara
  • Patent number: 10526273
    Abstract: Disclosed herein are surfactant compounds, that are surface active, liquid, chiral, and micelle forming. Also disclose herein are ionic liquids and compsitions comprising the surfactant compounds.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: January 7, 2020
    Assignee: Vanderbilt University
    Inventors: Prasad L. Polavarapu, Vijay Raghavan
  • Patent number: 10526274
    Abstract: Prostacyclin compounds and compositions comprising the same are provided herein. Specifically, prostacyclin compounds comprising treprostinil covalently linked to a linear C5-C18 alkyl, branched C5-C18 alkyl, linear C2-C18 alkenyl, branched C3-C18 alkenyl, aryl, aryl-C1-C18 alkyl or an amino acid or a peptide (e.g., dipeptide, tripeptide, tetrapeptide) are described. The linkage, in one embodiment, is via a carbamate, amide or ester bond. Prostacyclin compounds provided herein can also include at least one hydrogen atom substituted with at least one deuterium atom. Methods for treating pulmonary hypertension (e.g., pulmonary arterial hypertension) and portopulmonary hypertension are also provided.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: January 7, 2020
    Assignee: INSMED INCORPORATED
    Inventors: Vladimir Malinin, Walter Perkins, Franziska Leifer, Donna Konicek, Zhili Li, Adam Plaunt
  • Patent number: 10526275
    Abstract: Systems and method are provided for reducing the water content in ethanolamine product streams from approximately 0.15%-0.19% by weight of water to approximately 0.02 to approximately 0.04 by weight of water. The reduced water content can be achieved by increasing the processing conditions at the monoethanolamine column by approximately 5% to approximately 20%, more preferably to approximately 10%, and by adding a dummy stream to the monoethanolamine column, which can be recycled to the reactor. The increased processing conditions and dummy stream at the monoethanolamine column can result in the following to achieve said water content: (i) the bottom stream flow rate increase by up to approximately 18.9%; the reboiler duty can be increased by up to 47.9%; and (iii) the condenser duty can be increased by up to approximately 52.5%.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: January 7, 2020
    Assignee: SABIC GLOBAL TECHNOLOGIES B.V.
    Inventor: Naeem Al-Hazmi
  • Patent number: 10526276
    Abstract: The present invention relates to a group of compounds with a structural nucleus derived from phenylacetamide, having the following formula (I): that can modulate the DREAM neuronal calcium sensor. Consequently, the present invention also relates to the use of these compounds for the treatment or prevention of disorders or diseases in which DREAM levels are above or below physiologically normal levels.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: January 7, 2020
    Assignees: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS, CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES NEURODEGENERATIVAS (CIBERNED), UNIVERSIDAD AUTÓNOMA DE MADRID
    Inventors: Marta Gutiérrez Rodríguez, Pilar Cercos Pita, María Rosario Herranz Herranz, María Teresa García López, María Carmen Valenzuela Miranda, José Ramón Naranjo Orovio, Britt Mellstrom, Paz González Pérez, María Mercedes Martín Martínez, José Manuel Dopazo Santos
  • Patent number: 10526277
    Abstract: Di(amido(alkyl)phenol) compounds and upgraded molecular weight polymers made from such compounds have particular utility in coating compositions, especially for use on food and beverage contact substrates that are formed into or will be formed into containers or container components.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: January 7, 2020
    Assignee: SWIMC LLC
    Inventors: Sebastien Gibanel, Benoit Prouvost, Bernard Boutevin
  • Patent number: 10526278
    Abstract: Modulation of quorum sensing in Gram-negative bacteria, particularly strains of Pseudomonas which form biofilms, by compounds including those of formula I and formula II: where: AR is optionally substituted phenyl, cycloalkyl or cycloalkenyl or heterocyclic, and R1 is optionally substituted alkyl, alkenyl, alkoxyalkyl, or alkylthioalkyl or alkyl substituted at the omega position with optionally substituted phenyl, cyclohexyl or cyclohexenyl. In particular compounds inhibit quorum sensing and biofilm formation. Pharmaceutical compositions for treatment of bacterial infections and methods of treatment of such infections are provided.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: January 7, 2020
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Helen Blackwell, Daniel Manson
  • Patent number: 10526279
    Abstract: The present invention provides a process for the preparation of Teriflunomide (Formula-I). The present invention describes the synthesis of Teriflunomide without isolating the intermediate Leflunomide. Teriflunomide is prepared from 5-Methyl isoxazole-4-carboxylic acid by converting to its acid chloride and coupling with 4-trifluoromethyl aniline to obtain Leflunomide (which is not isolated) followed by ring opening reaction using aq. Sodium Hydroxide to form Teriflunomide. In other words, the process is telescoped from 5-methylisoxazole-4-carbonyl chloride.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: January 7, 2020
    Assignee: BIOCON LIMITED
    Inventors: Venkata Raghavendracharyulu Palle, Ramakrishna Parameshwar Bhat, Mariappan Kaliappan, Jithendra R. Babu, Rajmahendra Shanmughasamy
  • Patent number: 10526280
    Abstract: A compound, or pharmaceutically acceptable salt thereof, having a formula I of: wherein R1 is H or optionally-substituted alkyl; R2 is optionally-substituted alkyl; R3 and R4 are each independently H or optionally-substituted alkyl; R5 is H, optionally-substituted alkyl, acyl, or alkoxycarbonyl; R6 and R7 are each independently H, deuterium, optionally-substituted alkyl, or R6 and R7 together form a carbocyclic; R8 is optionally-substituted thiazolyl, optionally-substituted thiophenyl, or substituted phenyl, provided that if R8 is 4-halophenyl, then R2 is substituted alkyl or branched alkyl or at least one of R6 or R7 is not H; and R30, R31 and R32 are each independently H, deuterium, halogen, substituted sulfanyl, or optionally-substituted alkoxy.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: January 7, 2020
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Peter Wipf, Athanassios Tzounopoulos
  • Patent number: 10526281
    Abstract: Disclosed is a novel method of controlling the formation of biuret in urea production, and particularly reducing, preventing or reversing such formation. This is accomplished by adding liquid ammonia to a urea aqueous stream. This addition is done at one or more positions downstream of a recovery section in a urea plant. The addition of liquid ammonia serves to shift the equilibrium of biuret formation from urea, to the side of the formation of urea from biuret and ammonia. The invention can be accomplished also in pre-existing urea plant, by the simple measure of providing an appropriate inlet for liquid ammonia, in fluid communication with a source of such liquid ammonia.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: January 7, 2020
    Assignee: STAMICARBON B.V.
    Inventor: Eelco Mostert
  • Patent number: 10526282
    Abstract: The present specification relates to a fluorine-based compound for a brancher, a polymer using the same, a polymer electrolyte membrane using the same, a fuel cell using the same, and a redox flow battery including the same.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: January 7, 2020
    Assignee: LG CHEM, LTD.
    Inventors: Hyun Woog Ryu, Sehee Jung, Joong Jin Han, Yong Jin Jang, Youngjea Kim, Esder Kang
  • Patent number: 10526283
    Abstract: Provided are mucolytic compounds that are more effective, and/or absorbed less rapidly from mucosal surfaces, and/or are better tolerated as compared to N-acetylcysteine (NAC) and DTT. The compounds are represented by compounds of Formula I which embrace structures (Ia)-(Ib): where the structural variables are as defined herein.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: January 7, 2020
    Assignee: PARION SCIENCES, INC.
    Inventors: Michael Ross Johnson, William R. Thelin
  • Patent number: 10526284
    Abstract: What is described is a compound of formula I consisting of a compound in which R1 is a branched chain alkyl consisting of 10 to 31 carbons; R2 is a linear alkyl, alkenyl, or alkynyl consisting of 2 to 20 carbons, or a branched chain alkyl consisting of 10 to 31 carbons; L1 and L2 are the same or different, each a linear alkane of 1 to 20 carbons or a linear alkene of 2 to 20 carbons; X1 is S or O; R3 is a linear or branched alkylene consisting of 1 to 6 carbons; and R4 and R5 are the same or different, each a hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: January 7, 2020
    Assignee: ARCTURUS THERAPEUTICS, INC.
    Inventors: Joseph E. Payne, Padmanabh Chivukula, Priya Karmali, Steven P. Tanis
  • Patent number: 10526285
    Abstract: The invention provides compounds having the general Formula (I); and pharmaceutically acceptable salts thereof; wherein the variables RA, RAA, subscript n, subscript q, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, D and E have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: January 7, 2020
    Assignees: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Jean-Christophe Andrez, Philippe Bergeron, Paul Robert Bichler, Sultan Chowdhury, Christoph Martin Dehnhardt, Thilo Focken, Wei Gong, Michael Edward Grimwood, Abid Hasan, Ivan William Hemeon, Qi Jia, Brian Salvatore Safina, Shaoyi Sun, Michael Scott Wilson, Alla Yurevna Zenova
  • Patent number: 10526286
    Abstract: The present specification provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ROR? and/or ROR?t mediated disease state.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: January 7, 2020
    Assignee: AstraZeneca AB
    Inventors: Frank Narjes, Roine Ingemar Olsson, Stefan Von Berg, Sarah Lever
  • Patent number: 10526287
    Abstract: Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSD1. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with LSD1.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: January 7, 2020
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Brian K. Albrecht, James Edmund Audia, Alexandre Côté, Martin Duplessis, Victor S. Gehling, Jean-Christophe Harmange, Rishi G. Vaswani
  • Patent number: 10526288
    Abstract: The object of the present invention is to provide a method for preparing 4-(piperidin-4-yl)morpholine, which is easy to operate. The object can be solved by a method for preparing 4-(1-benzylpiperidin-4-yl)morpholine, characterized in that 5-fold molar or more of morpholine is added to 1-benzyl-4-piperidone, and the mixture is reacted with hydrogen under 1 MPa or less in the presence of platinum catalyst or palladium catalyst.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: January 7, 2020
    Assignee: YUKI GOSEI KOGYO CO., LTD.
    Inventors: Hiromi Ishikawa, Kiyono Nakagawa, Yukiko Takeda
  • Patent number: 10526289
    Abstract: The present invention relates to the identification of compounds and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The invention also provides methods of preparing the provided compounds.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: January 7, 2020
    Assignee: Northwestern University
    Inventors: Richard B. Silverman, Yinan Zhang
  • Patent number: 10526290
    Abstract: The present invention relates to bendamustine derivatives and related compounds of formula (VII), (VIII) and (IX), and medical uses thereof in particular in cancer therapy.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: January 7, 2020
    Assignee: SYNBIAS PHARMA AG
    Inventors: Helmut Schickaneder, Christian Schickaneder, Armin Buschauer, Stefan Huber, Michael Limmert, Günther Bernhardt, Mathias Lubbe, Harald Hofmeier
  • Patent number: 10526291
    Abstract: Disclosed herein are compounds that are inhibitors of BRD4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BRD4 are also disclosed. In certain aspects, disclosed are compounds of Formula I-IV.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: January 7, 2020
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Ernst Schönbrunn, Nicholas J. Lawrence, Harshani R. Lawrence, Gary W. Reuther
  • Patent number: 10526292
    Abstract: Sodium channel blockers represented by the formula: are provided where the structural variables are defined herein. The invention also includes a variety of compositions, combinations and methods of treatment using these inventive sodium channel blockers.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: January 7, 2020
    Assignee: Parion Sciences, Inc.
    Inventors: Michael Ross Johnson, William Robert Thelin, Richard C. Boucher
  • Patent number: 10526293
    Abstract: This method for producing a fullerene derivative is a method for producing a fullerene derivative having a partial structure shown by formula (1) by reacting a predetermined halogenated compound and two carbon atoms adjacent to each other for forming a fullerene skeleton in a mixed solvent of an aromatic solvent and an aprotic polar solvent having a C?O or S?O bond in the presence of at least one metal selected from the group comprising manganese, iron, and zinc; (in formula (1), C* are each carbon atoms adjacent to each other for forming a fullerene skeleton, A is a linking group having 1-4 carbon atoms for forming a ring structure with two C*, in which a portion thereof may be a substituted or condensed group).
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: January 7, 2020
    Assignees: SHOWA DENKO K.K., MITSUBISHI CORPORATION
    Inventors: Tienan Jin, Weili Si, Yoshinori Yamamoto, Takeshi Igarashi
  • Patent number: 10526294
    Abstract: The present disclosure relates generally to derivatives of pyrrolobenzodiazepines and antibody-drug conjugates thereof and to methods of using these conjugates as therapeutics and/or diagnostics.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: January 7, 2020
    Assignee: Mersana Therapeutics, Inc.
    Inventors: Joshua D. Thomas, Mao Yin, Aleksandr V. Yurkovetskiy, Patrick R. Conlon, Ahmed Hilmy, Eugene W. Kelleher, Timothy B. Lowinger, Cheri A. Stevenson, Shuyi Tang
  • Patent number: 10526295
    Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I or their pharmaceutically acceptable salts, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: January 7, 2020
    Assignee: Karyopharm Therapeutics Inc.
    Inventor: Erkan Baloglu
  • Patent number: 10526296
    Abstract: Described are high energy light blocking compounds and ophthalmic devices containing the compounds. In particular, described are hydroxyphenyl naphthotriazole structures with polymerizable functionality that block high energy light and are visibly transparent. The hydroxyphenyl naphthotriazole structures can be incorporated into ophthalmic devices, such as hydrogel contact lenses, to protect eyes from high energy light radiation.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: January 7, 2020
    Assignee: Johnson & Johnson Vision Care, Inc.
    Inventors: Shivkumar Mahadevan, Leilani K. Sonoda, Dola Sinha, Patricia Martin
  • Patent number: 10526297
    Abstract: The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, wherein R1 is alkyl, Cl, F or Br, R2 is H or F; R3 is selected from H and alkyl; R4 is selected from H and C(O)R6; R5 is H or R4 and R5 are linked to form a heterocyclic group which is optionally substituted with one or more R10 groups R6 is selected from R7, OR7 and NR8R6; R7R8 and R9 are each independently selected from alkyl, cycloalkyl, aralkyl, cycloalkenyl, heterocycyl and aryl, each of which is optionally substituted with one or more R10 groups; each R10 is independently selected from halogen, OH, CN NO1, COO-alkyl, aralkyl, SO2-alkyl, SO2-aryl, COOH, CO-alkyl, CO-aryl, NH2, NH-alkyl, N(alkyl)2, CF3, alkyl and alkoxy, X and Z are each independently CR11 and Y is selected from CR11 and N and R11 is H or F; for use in treating a disorder associated with protein misfolding stress and in particular associated with accumulation of misfolded proteins.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: January 7, 2020
    Assignees: InFlectis BioScience, United Kingdom Research and Innovation
    Inventors: Philippe Guedat, Anne Bertolotti
  • Patent number: 10526298
    Abstract: Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions, including but not limited to diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and nonalcoholic steatohepatitis (NASH); ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: January 7, 2020
    Assignee: EPIGEN BIOSCIENCES, INC.
    Inventors: Graham Beaton, Fabio C. Tucci, Satheesh B. Ravula, Chandravadan R. Shah, Hiep Luu
  • Patent number: 10526299
    Abstract: An apparatus includes a conduit with two process fluid inlets at one end of the conduit, one process fluid outlet at an opposing end, a heat exchange medium inlet, and a heat exchange medium outlet. One of the fluid inlets includes a tube extending into the conduit and a perforated node at the end of the tube, and the other of the fluid inlets is arranged up stream of the perforated node. The apparatus further includes hollow tubes positioned longitudinally within the conduit between the two process fluid inlets, the process fluid outlet, the heat exchange medium inlet and the heat exchange medium outlet. In addition, the apparatus includes a collection vessel positioned proximate the fluid outlet and fibers extending through each of the hollow tubes, wherein one end of the fibers is secured to the perforated node and the other end of the fibers extends into the collection vessel.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: January 7, 2020
    Assignee: Chemtor, LP
    Inventor: John Lee Massingill
  • Patent number: 10526300
    Abstract: Processes for reducing the amount of a gaseous iodide-containing impurity present in a recycle gas stream used in the production of ethylene oxide, in particular alkyl iodide and vinyl iodide impurities, are provided. Processes for producing ethylene oxide, ethylene carbonate and/or ethylene glycol, and associated reaction systems are similarly provided.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: January 7, 2020
    Assignee: SHELL OIL COMPANY
    Inventors: Wayne Errol Evans, Jesse Raymond Black, Michael Francis Lemanski
  • Patent number: 10526301
    Abstract: Disclosed is a process to produce a purified vapor comprising dialkyl-furan-2,5-dicarboxylate (DAFD). Furan-2,5-dicarboxylic acid (FDCA) and an alcohol in an esterification zone to generate a crude diester stream containing dialkyl furan dicarboxylate (DAFD), unreacted alcohol, 5-(alkoxycarbonyl)furan-2-carboxylic acid (ACFC), and alkyl furan-2-carboxylate (AFC). The esterification zone comprises at least one reactor that has been previously used in an DMT process.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: January 7, 2020
    Assignee: Eastman Chemical Company
    Inventors: Kevin John Fontenot, Mesfin Ejerssa Janka, Kenny Randolph Parker, Ashfaq Shahanawaz Shaikh
  • Patent number: 10526302
    Abstract: The invention relates to a process for the production of 5-hydroxymethylfurfural from a feedstock comprising at least one sugar using a combination of at least one catalyst selected from the homogeneous Lewis acids, the heterogeneous Lewis acids and the heterogeneous bases and at least one homogeneous Brønsted acid catalyst selected from the families of the thioureas, the sulphonic acids and the phosphorus-containing organic compounds, alone or in a mixture, in the presence of at least one aprotic polar solvent, at a temperature comprised between 30° C. and 300° C., and at a pressure comprised between 0.1 MPa and 10 MPa.
    Type: Grant
    Filed: October 17, 2016
    Date of Patent: January 7, 2020
    Assignee: IFP Energies Nouvelles
    Inventors: Myriam Souleymanou, Marc Jacquin, Damien Delcroix
  • Patent number: 10526303
    Abstract: In certain embodiments, the disclosure relates to 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, such as those described by formula provided herein, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing diseases or conditions related to BDNF and TrkB activity, such as psychiatric disorders, depression, post-traumatic stress disorder, and autism spectrum disorders, stroke, Rett syndrome, Parkinson's disease, and Alzheimer's disease by administering effective amounts of pharmaceutical compositions comprising compounds disclosed herein to a subject in need thereof. In certain embodiments, it is contemplated that the 7,8-substituted flavone derivatives disclosed herein are prodrugs of 7,8-dihydoxyflavone and analogs.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: January 7, 2020
    Assignee: Emory University
    Inventor: Keqiang Ye
  • Patent number: 10526304
    Abstract: The present invention relates to nebivolol synthesis method and intermediate compound thereof. Specifically, the present invention relates to a method for synthesizing nebivolol, intermediate compound thereof, and a method for preparing the intermediate compound.
    Type: Grant
    Filed: May 19, 2015
    Date of Patent: January 7, 2020
    Assignee: ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD.
    Inventor: Zhiguo Zheng
  • Patent number: 10526306
    Abstract: A method for purifying crystals in a glass or metal container. A hydrocarbon is introduced into feed material containing tetrahydrocannabinol (THC). The feed material and hydrocarbon is placed in a glass or metal container. The hydrocarbon is then removed within a few minutes after introduction, leaving at least some hydrocarbon in the feed material. Pressure is allowed to build within the container in an oven or in a jacketed vessel for 2-3 weeks. During this time, THC acid crystals precipitate out and fall to the bottom of the container. The contents of the container are poured into a Buchner funnel and a vacuum is applied thereto in order to pull terpenes into a beaker. The terpenes are placed into an oven in order to purge off any remaining solvent. The funnel is then scraped to acquire THC acid crystals.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: January 7, 2020
    Inventors: Pratt Bethers, David Goodman, III
  • Patent number: 10526307
    Abstract: Disclosed are compounds, for example, compounds of formula (I), (Formula (I) wherein R, R0, R1-R8, n, X, Y, Y?, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: January 7, 2020
    Assignee: ADT Pharmaceuticals, LLC
    Inventors: Gary A. Piazza, Xi Chen, Adam B. Keeton, Michael R. Boyd
  • Patent number: 10526308
    Abstract: The present invention regards new adipate-type compounds suitable as an intermediate in organic chemistry, a platform chemical for the production of other chemicals, and as a monomer and co-monomer useful for the preparation of polymers and copolymers. The invention also regards the process of preparing the new adipate-type compounds from bio-based raw materials such as sugars.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: January 7, 2020
    Assignee: HALDOR TOPSØE A/S
    Inventors: Esben Taarning, Amanda Birgitte Sølvhøj
  • Patent number: 10526309
    Abstract: This invention is in the area of improved therapeutic combinations for and methods of treating selected cancers using selected pyrimidine compounds having pan-TAM or Mer/Axl dual receptor tyrosine kinase inhibitory activity in combination with immune checkpoint inhibitors. In one aspect, an improved treatment for select cancers is disclosed using selected pyrimidine compounds described herein in combination with an immune checkpoint inhibitor, for example, a cytotoxic T-lymphocyte-associated protein 4 (CTLA4) inhibitor, a programmed cell death protein 1 (PD1) inhibitor, or a programmed death-ligand 1 (PDL-1) inhibitor, or combination thereof.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: January 7, 2020
    Assignee: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
    Inventors: Xiaodong Wang, Dehui Zhang, Dmitri Kireev, Henry Shelton Earp, III
  • Patent number: 10526310
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3,4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: January 7, 2020
    Assignees: Aragon Pharmaceuticals Inc., Sloan Kettering Institute for Cancer Research
    Inventors: Anna Dilhas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
  • Patent number: 10526311
    Abstract: The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: January 7, 2020
    Assignees: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Gianni Chessari, Steven Howard, Ildiko Maria Buck, Benjamin David Cons, Christopher Norbert Johnson, Rhian Sara Holvey, David Charles Rees, Jeffrey David St. Denis, Emiliano Tamanini, Bernard Thomas Golding, Ian Robert Hardcastle, Celine Florence Cano, Duncan Charles Miller, Martin Edward Mäntylä Noble, Roger John Griffin, James Daniel Osborne, Joanne Peach, Arwel Lewis, Kim Louise Hirst, Benjamin Paul Whittaker, David Wyn Watson, Dale Robert Mitchell
  • Patent number: 10526312
    Abstract: The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: January 7, 2020
    Assignee: Mycovia Pharmaceuticals, Inc.
    Inventors: William J. Hoekstra, Robert J. Schotzinger, Stephen W. Rafferty
  • Patent number: 10526313
    Abstract: BA-1049 (R) and its active metabolite are disclosed. Also disclosed are pharmaceutical formulations containing BA-1049 (R) or its active metabolite.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: January 7, 2020
    Assignee: BioAxone BioSciences, Inc.
    Inventors: Kenneth M. Rosen, Matthew D. Abbinanti, Joerg Ruschel, Lisa Mckerracher, Lisa Bond Moritz
  • Patent number: 10526314
    Abstract: The present invention relates to novel 5-(hydroxyalkyl)-1-heteroaryl-1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: January 7, 2020
    Assignees: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Marie-Pierre Collin-Kröpelin, Peter Kolkhof, Thomas Neubauer, Chantal Fürstner, Elisabeth Pook, Matthias Beat Wittwer, Carsten Schmeck, Pierre Wasnaire, Hanna Tinel, Heiko Schirmer
  • Patent number: 10526315
    Abstract: This invention is directed to novel carbocyclic prolinamide derivatives of Formula (I), and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry-AMD, wet-AMD, and geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells, comprising: administration of a therapeutically effective amount of compound of the invention.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: January 7, 2020
    Assignee: ORION OPHTHALMOLOGY LLC
    Inventors: Robert Gomez, Jinyue Ding, Renata Marcella Oballa, David Andrew Powell
  • Patent number: 10526316
    Abstract: The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: January 7, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick Rene Angibaud, Olivier Alexis Georges Querolle, Didier Jean-Claude Berthelot, Christophe Meyer, Matthieu Philippe Victor Willot, Lieven Meerpoel, Thierry Francois Alain Jean Jousseaume
  • Patent number: 10526317
    Abstract: Compounds useful as labels with properties comparable to known fluorescent compounds. The compounds are conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: January 7, 2020
    Assignees: Pierce Biotechnology, Inc., Dyomics GmbH
    Inventors: Greg Hermanson, Peter T. Czerney, Surbhi Desai, Matthias S. Wenzel, Boguslawa R. Dworecki, Frank G. Lehmann, Marie Christine Nlend
  • Patent number: 10526318
    Abstract: Oral formulations of benzofuran compounds which modulate cannabinoid receptors are presented. Methods of using these formulations for treatment of cannabinoid receptor-mediated disease, including neuropathic pain and addition, are also described.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: January 7, 2020
    Assignee: THE CLEVELAND CLINIC FOUNDATION
    Inventors: Joseph Foss, Mohamed Naguib Attala
  • Patent number: 10526319
    Abstract: The present invention provides halogenated quinazolin-THF-amines as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: January 7, 2020
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Lars Kyhn Rasmussen, Morten Langgård
  • Patent number: 10526320
    Abstract: The present invention discloses a class of pyrrolidine derivatives as PPAR agonist, and their use for the treatment of some diseases of PPAR receptor-associated pathways (such as nonalcoholic steatohepatitis and concurrent fibrosis, insulin resistance, primary biliary cholangitis, dyslipidemia, hyperlipidemia, hypercholesterolemia, atherosclerosis, hypertriglyceridemia, cardiovascular disease, obesity or the like). In particular, the present invention discloses a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: January 7, 2020
    Assignee: GUANGDONG RAYNOVENT BIOTECH CO., LTD.
    Inventors: Zhiliang Yuan, Chaofeng Long, Zhigan Jiang, Xiaoxin Chen, Haiying He, Xing Liu, Xiao Zhang, Zhiqiang Liu, Yan Wang, Leilei Gao, Zhen Gong, Jian Li, Shuhui Chen
  • Patent number: 10526321
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: January 7, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Stephen T. Wrobleski, Shuqun Lin